Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review

Yasuhiro Shimojima, Masayuki Matsuda, Wataru Ishii and Shu-ichi Ikeda
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Corresponding author email: matsuma@shinshu-u.ac.jp

Abstract: We report a patient with psoriatic arthritis (PsA) who was successfully treated with adalimumab even while under hemodialysis therapy for associated chronic renal failure. Flow cytometry of circulating lymphocytes revealed an obvious decrease in both Th1 and Th17 cells after starting adalimumab. The latter returned to the pretreatment level in the course of adalimumab therapy, while the former did not. Adalimumab is a potent therapeutic option for PsA patients with chronic renal failure on hemodialysis, and Th1 in peripheral blood may reflect the disease activity.

Keywords: adalimumab, psoriatic arthritis, hemodialysis, Th1, Th17
Introduction
Psoriasis is a chronic inflammatory skin disease characterized clinically by red scaly patches developing in any part of the body with a relapse-remitting course. Systemic arthritis complicates psoriasis in approximately 20% of the patients,1 and its clinical picture resembles that of rheumatoid arthritis with regard to therapeutic efficacy of the monoclonal anti-tumor necrosis factor (TNF)-α antibody, such as infliximab and adalimumab. Several recent reports have demonstrated that T-helper 1 cells (Th1), T-helper 17 cells (Th17) and regulatory T cells (Treg) may play a central role in the pathogenesis of psoriatic arthritis (PsA) via interaction with dendritic cells, leading to accelerated production of TNF.2,3 Here, we report a patient with PsA associated with chronic renal failure on hemodialysis who was successfully treated with adalimumab alone. Flow cytometry showed a persistent decrease in Th1 cells after starting adalimumab, and we postulate that this circulating lymphocyte subpopulation may be useful as a therapeutic marker of PsA.

Case Report
A 57-year-old man with a 9-year history of hemodialysis for chronic renal failure due to glomerulonephritis became aware of arthralgia in multiple joints with no precipitating cause. He was treated with oral prednisolone at a dose of 5 to 7.5 mg daily in a neighboring hospital, but systemic arthralgia worsened gradually. When he was referred to our hospital, physical examination showed swelling and tenderness in bilateral proximal interphalangeal (PIP) joints, wrists, knees, ankles and metatarsophalangeal joints with no significant skin lesions. Laboratory tests demonstrated an increase in inflammatory reactions, such as C-reactive protein (CRP) (1.28 mg/dL, normal <0.1 mg/dL) and renal dysfunction (creatinine 4.28 mg/dL, normal 0.6–1.0 mg/dL; blood urea nitrogen 78.5 mg/dL, normal 8–20 mg/dL) but no positive results in autoantibodies, including rheumatoid factor and the anti-cyclic citrullinated peptide and anti-nuclear antibodies. The X-ray showed mild bone erosions on PIP joints. The disease activity score including a 28-joint count (DAS28)-CRP calculated according to the approved formula (http://www.das-score.nl/) was 3.79. Salazosulfapyridine at 1000 mg daily could not sufficiently relieve his arthralgia.

Approximately 10 months later he noticed eruptions on his head, elbows, fingers and knees with hyperkeratosis and discoloration in his nails, which were clinically diagnosed as psoriasis by a dermatologist, in conjunction with worsening of his systemic arthritis and elevations of CRP (3.31 mg/dL) (Fig. 1). The psoriasis area and severity index (PASI) was relatively low (6.0), but DAS28-CRP indicated high disease activity of arthritis (6.88). Adalimumab was started at 80 mg initially, followed by 40 mg every other week. The patient showed dramatic improvement of his arthritis as well as psoriasis, and DAS28-CRP and PASI decreased to 2.41 and 2.8, respectively, 2 weeks after starting adalimumab (Fig. 2). On flow cytometry before treatment CD4+ interferon-γ (Th1) and CD4+ interleukin-17+ (Th17) cells in peripheral blood were higher than those of age-matched healthy controls, but CD4+CD25+FOXP-3+ cells (Treg) showed no obvious increase. All of these lymphocyte subpopulations were decreased eight weeks after starting adalimumab compared with before (Fig. 2). CD4+ interleukin-4+ cells (T-helper 2) showed no significant change before and after treatment. Twelve weeks after starting adalimumab, CD4+ interleukin-17+ and CD4+CD25+FOXP-3+ cells returned to the pretreatment level but CD4+ interferon-γ cells remained at low levels. He has since been in good general health.
with no arthralgia or adverse events under regular administration of adalimumab.

**Discussion**

The present patient was diagnosed as having PsA based on polyarthritis with skin and nail lesions characteristic of psoriasis. In approximately 19% of PsA polyarthritis has been reported to precede psoriasis, as seen in the present patient. Methotrexate and cyclosporine A are usually potent therapeutic options for PsA, but these drugs were inadequate in the present patient because of chronic renal failure requiring hemodialysis. Biologics are the next choice. Several recent reports have demonstrated that early use of biologics can ameliorate polyarthralgia and skin lesions in rheumatic disorders, including PsA, associated with chronic renal failure on hemodialysis (Table 1). Biologics targeting TNF are most frequently used in this situation, and among them etanercept has been reported to show pharmacokinetics similar to those in healthy subjects even under chronic renal failure on hemodialysis. However, the use of etanercept is not allowed in PsA in Japan. In the present patient, therefore, we decided to employ adalimumab, which is a human anti-TNF-α monoclonal antibody usable in PsA without coadministrations of methotrexate. The usual dose of adalimumab is 40 mg, but 80 mg was selected as an initial dose in the present patient because of severe systemic arthritis. Soon after starting this drug both polyarthralgia and psoriasis improved in parallel with a decrease in inflammatory reactions. The patient has so far shown no serious adverse events ascribable to adalimumab.

In the present patient we serially analyzed phenotypes of peripheral blood lymphocytes using flow cytometry. Th1 and Th17 cells showed significantly higher levels before treatment compared with those of age-matched healthy controls as described in the previous report from another institute, but Treg cells did not. These 3 lymphocyte subpopulations manifestly decreased 8 weeks after starting adalimumab. Th17 and Treg cells returned to the pretreatment level 12 weeks after starting adalimumab, while Th1 cells remained at low levels in conjunction with
Table 1. Reported cases with biologics therapy in rheumatic diseases associated with renal failure.

| Author | Onset age/sex | Rheumatic diseases | Cause of renal failure | Duration of HD or PD on starting biologics therapy | Biologics used | Outcome of rheumatic diseases | Adverse events |
|--------|---------------|--------------------|------------------------|---------------------------------------------------|----------------|------------------------------|----------------|
| Yee    | 72/F          | Sarcoidosis        | Drug-induced acute tubular necrosis | Several weeks                                      | Infliximab     | Improved                     | Hypercoagulation |
| Singh  | 60/F          | RA                 | Hypertensive nephrosclerosis | Several months                                     | Infliximab     | Improved                     | None            |
| Hammoudeh | 45/F       | RA                 | Chronic glomerulonephritis and chronic rejection of transplanted kidney | 9 years                                           | Infliximab     | Improved                     | Transient itching |
| Sugioka | 64/F          | RA                 | Chronic glomerulonephritis | 2 years                                           | Etanercept     | Improved                     | None            |
| Cassano | 69/M          | Psoriasis          | Autosomal polycystic kidney | 9 years                                           | Etanercept     | Improved                     | None            |
| Kobak  | 65/M          | AS                 | ND                      | 6 years                                           | Adalimumab     | Improved                     | None            |
| Saougou | 52/M          | PsA                | Chronic glomerulonephritis | 2 years                                           | Infliximab     | Improved                     | None            |
| Iwamoto | 64/M          | RA                 | Drug-induced renal failure | 15 years                                          | Tocilizumab    | Improved                     | None            |
| Present patient | 58/M   | PsA                | Chronic glomerulonephritis | 11 years                                          | Adalimumab     | Improved                     | None            |

Abbreviations: AS, ankylosing spondylitis; HD, hemodialysis; ND, not described; PD, peritoneal dialysis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.

Acknowledgment
This work was supported by grant from Eisai Co., Ltd., and the Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan.

In conclusion, adalimumab monotherapy is a potent therapeutic option in patients with PsA with regard to clinical efficacy and safety even under hemodialysis for associated chronic renal failure. Further studies may be able to more sensitively reflect disease activity in a set of patients are necessary in order to clarify whether or not Th1 cells are a useful clinical marker indicating disease activity of PsA.

The suppressed activity of PsA. The decreases in Th1, Th17 and Treg cells after treatment are ascribable to 3 possible mechanisms. The first is a direct cytotoxic effect of adalimumab. The second possible mechanism is anti-TNF-mediated recovery of these lymphocytes, such as Th17 and Treg cells, resulting in a rapid elimination of Th1, Th17 and Treg cells. The third possible mechanism is anti-TNF-mediated reduction of this cytokine in peripheral blood via some other stimulating mediators, such as interleukin-2 and transforming growth factor-β.

In conclusion, adalimumab is able to more sensitively reflect disease activity in a set of patients are necessary in order to clarify whether or not Th1 cells are a useful clinical marker indicating disease activity of PsA.

The interaction between TNF-α on the cell surface and adalimumab may have produced cytokine, resulting in a rapid elimination of Th1, Th17 and Treg cells. This phenomenon has multipotential on immune systems. As TNF-α can promote differentiation of T cells into Th17 and Treg cells, the third possible mechanism is anti-TNF-mediated reduction of this cytokine in peripheral blood via some other stimulating mediators, such as interleukin-2 and transforming growth factor-β.
Disclosures
Author(s) have provided signed confirmations to the publisher of their compliance with all applicable legal and ethical obligations in respect to declaration of conflicts of interest, funding, authorship and contributorship, and compliance with ethical requirements in respect to treatment of human and animal test subjects. If this article contains identifiable human subject(s) author(s) were required to supply signed patient consent prior to publication. Author(s) have confirmed that the published article is unique and not under consideration nor published by any other publication and that they have consent to reproduce any copyrighted material. The peer reviewers declared no conflicts of interest.

References
1. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdiscipli- nary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040–7.
2. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondyloarthritides. Arthritis Rheum. 2008;58:2307–17.
3. Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW. Increased Th17 cells are accompanied by FoxP3+ Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol. 2010;135:108–17.
4. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984;23:246–50.
5. Saougu I, Papagoras C, Markatseli TE, Voulgari PV, Drosos AA. A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocker agent and a literature review. Clin Rheumatol. 2010. [Epub ahead of print.]
6. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135: 27–31.
7. Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29: 636–7.
8. Hammadouche M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006;45:357–9.
9. Sugio K, Inui K, Koike T. Use of etanercept in a patient with rheumatoid arthritis on haemodialysis. Mod Rheumatol. 2008;18:293–5.
10. Cassaro N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol. 2008;47:980–1.
11. Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol Int. 2010. [Epub ahead of print.]
12. Iwamoto M, Honna S, Asano Y, Minota S. Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis. Rheumatol Int. 2010. [Epub ahead of print.]
13. Don BR, Spin G, Nesterov I, Huttmacher M, Rose A, Kaysern GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005;57:1407–13.
14. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–88.
15. Mitoma H, Horiiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248–57.
16. Aravena O, Pesce B, Soto L, et al. Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets. Immunobiology. 2011;216:1256–63.
17. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142–51.
18. D’Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol. 2005;6:1152–9.
19. Marie JC, Lettiero JJ, Gavin M, Rudensky AY. TGFβ1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:1061–7.
20. Zhang J, Hua G, Zhang X, Tong R, Du X, Li Z. Regulatory T cells/ T-helper cell 17 functional imbalance in uraemic patients on maintenance haemodialysis: a pivotal link between microinflammation and adverse cardiovascular events. Nephrology. 2010;15:33–41.

Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:
• Available to your entire community free of charge
• Fairly and quickly peer reviewed
• Yours! You retain copyright

http://www.la-press.com